Mark O’Connor

Company: AstraZeneca

Job title: Chief Scientist

Seminars:

Reverse Translation of First Generation Clinical PARP Inhibitors to Inform Next Generation PARPi-Based Medicines 9:00 am

• Understanding key aspects of PARPi MoA: PARP selectivity, trapping characteristics and HRD-specificity • Exploring additional PARPi characteristics that contribute towards clinical tolerability profiles (such as secondary pharmacology and plasma vs bone marrow distribution)Read more

day: Day One

Panel Discussion: What Makes the Perfect Next-Generation DDR Inhibitor Target? 4:30 pm

• How does protein size and function impact small molecule approaches? • Where does pathway redundancy fit into the journey of finding new targets? • Why have next generation targets been less successful moving through clinical phases?Read more

day: Day One